After successful PCI for AMI and 1 mo of DAPT, P2Y12 inhibitor monotherapy was noninferior to continued DAPT for adverse outcomes. Bates ER. Ann Intern Med 2025;178:JC136.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Bates ER. After successful PCI for AMI and 1 mo of DAPT, P2Y12 inhibitor monotherapy was noninferior to continued DAPT for adverse outcomes. Ann Intern Med 2025;178:JC136.
PMID: 41325612